Form D · Biotechnology
Checkpoint Therapeutics, Inc.
Waltham, MA · CIK 0001651407
Offering snapshot reported Jul 10, 2024 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 2, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 10, 2024 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 5, 2024 | Initial | $0 | No comparison | 1 | SEC filing |
| Apr 14, 2023 | Initial | $0 | No comparison | 9 | SEC filing |
| Mar 3, 2023 | Initial | $0 | No comparison | 1 | SEC filing |
| Sep 13, 2016 | Initial | $57,817,000 | No comparison | 559 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-518335
Checkpoint publicly sold $11,999,538 of common stock and equivalents and concurrently privately issued warrants and placement agent warrants pursuant to Rule 506(b) for up to 5,853,659 and up to 351,220 shares of common stock, respectively.
Checkpoint paid approximately $900,000 in fees and expenses in connection with the public offering and concurrent private placement. Such fees included a $840,000.07 cash fee and $60,000 of non-accountable expenses.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 |
Source: Form D, filed Jul 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christian Bechon | Director |
| Scott Boilen | Director |
| Garrett Gray | Executive |
| Neil Herskowitz | Director |
| David J. Horin | Executive |
| James F. Oliviero, Iii | Director, Executive |
| Lindsay A. Rosenwald | Director |
| Barry Salzman | Director |
| Amit Sharma | Director |
| Michael Weiss | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
95 Sawyer Road Suite 110
Waltham, MA, 02453
Waltham, MA, 02453